A detailed history of Samlyn Capital, LLC transactions in Merus N.V. stock. As of the latest transaction made, Samlyn Capital, LLC holds 2,610,393 shares of MRUS stock, worth $117 Million. This represents 2.1% of its overall portfolio holdings.

Number of Shares
2,610,393
Previous 2,324,195 12.31%
Holding current value
$117 Million
Previous $138 Million 5.17%
% of portfolio
2.1%
Previous 2.45%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$47.19 - $58.84 $13.5 Million - $16.8 Million
286,198 Added 12.31%
2,610,393 $130 Million
Q2 2024

Aug 14, 2024

BUY
$39.81 - $60.2 $9.86 Million - $14.9 Million
247,605 Added 11.92%
2,324,195 $138 Million
Q1 2024

May 15, 2024

SELL
$28.03 - $51.82 $37.4 Million - $69.2 Million
-1,335,820 Reduced 39.15%
2,076,590 $93.5 Million
Q4 2023

Feb 14, 2024

BUY
$20.06 - $28.66 $3.13 Million - $4.47 Million
155,892 Added 4.79%
3,412,410 $93.8 Million
Q3 2023

Nov 14, 2023

BUY
$20.13 - $27.29 $8.44 Million - $11.4 Million
419,069 Added 14.77%
3,256,518 $76.8 Million
Q2 2023

Aug 14, 2023

BUY
$18.33 - $27.18 $22.4 Million - $33.3 Million
1,224,022 Added 75.86%
2,837,449 $74.7 Million
Q1 2023

May 15, 2023

BUY
$14.25 - $20.5 $11.2 Million - $16.1 Million
787,340 Added 95.31%
1,613,427 $29.7 Million
Q4 2022

Feb 14, 2023

BUY
$12.8 - $23.66 $2.67 Million - $4.93 Million
208,442 Added 33.75%
826,087 $12.8 Million
Q3 2022

Nov 14, 2022

BUY
$18.64 - $28.93 $11.5 Million - $17.9 Million
617,645 New
617,645 $12.4 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.06B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Samlyn Capital, LLC Portfolio

Follow Samlyn Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Samlyn Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Samlyn Capital, LLC with notifications on news.